PubRank

Niacin Plus Statin to Prevent Vascular Events

Clinical Trial ID NCT00120289

PubWeight™ 61.69‹?›

🔗 Visit the ClinicalTrials.gov page for NCT00120289

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 2011 15.30
2 Major lipids, apolipoproteins, and risk of vascular disease. JAMA 2009 10.58
3 2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult - 2009 recommendations. Can J Cardiol 2009 5.65
4 Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J 2010 4.31
5 Summary of evidence-based guideline: periprocedural management of antithrombotic medications in patients with ischemic cerebrovascular disease: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology 2013 2.15
6 Dyslipidemia and cardiovascular risk: the importance of early prevention. QJM 2009 2.14
7 ASA failure: does the combination ASA/clopidogrel confer better long-term vascular protection? Neurology 2014 2.08
8 Update on strategies to increase HDL quantity and function. Nat Rev Cardiol 2009 1.94
9 Novel HDL-directed pharmacotherapeutic strategies. Nat Rev Cardiol 2011 1.91
10 The role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low-density lipoprotein cholesterol Rationale and study design. The Atherothrombosis Intervention in Metabolic syndrome with low HDL/high triglycerides: Impact on Global Health outcomes (AIM-HIGH). Am Heart J 2011 1.17
11 Cardiovascular drug therapy in the elderly: benefits and challenges. Nat Rev Cardiol 2010 1.13
12 Relationship of lipoproteins to cardiovascular events: the AIM-HIGH Trial (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides and Impact on Global Health Outcomes). J Am Coll Cardiol 2013 1.10
13 The role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low-density lipoprotein cholesterol: baseline characteristics of study participants. The Atherothrombosis Intervention in Metabolic syndrome with low HDL/high triglycerides: impact on Global Health outcomes (AIM-HIGH) trial. Am Heart J 2011 1.04
14 Longer duration of statin therapy is associated with decreased carotid plaque vascularity by magnetic resonance imaging. Atherosclerosis 2015 0.98
15 Atheroprotective lipoprotein effects of a niacin-simvastatin combination compared to low- and high-dose simvastatin monotherapy. Am Heart J 2009 0.87
16 Opening a new lipid "apo-thecary": incorporating apolipoproteins as potential risk factors and treatment targets to reduce cardiovascular risk. Mayo Clin Proc 2011 0.87
17 Reducing vascular events risk in patients with dyslipidaemia: an update for clinicians. Ther Adv Chronic Dis 2011 0.85
18 Familial Hypercholesterolemia: a Review of the Natural History, Diagnosis, and Management. Cardiol Ther 2015 0.83
19 Effects of niacin on atherosclerosis and vascular function. Curr Opin Cardiol 2011 0.80
20 Imaging outcomes in cardiovascular clinical trials. Nat Rev Cardiol 2009 0.80
21 Effects of Extended-Release Niacin Added to Simvastatin/Ezetimibe on Glucose and Insulin Values in AIM-HIGH. Am J Med 2016 0.79
22 Extended-release niacin therapy and risk of ischemic stroke in patients with cardiovascular disease: the Atherothrombosis Intervention in Metabolic Syndrome with low HDL/High Triglycerides: Impact on Global Health Outcome (AIM-HIGH) trial. Stroke 2013 0.79
23 Niacin extended release (ER)/simvastatin (Simcor®): a guide to its use in lipid regulation. Drugs R D 2010 0.79
24 Prolonged-release nicotinic acid for the management of dyslipidemia: an update including results from the NAUTILUS study. Vasc Health Risk Manag 2007 0.78
25 Safety and efficacy of laropiprant and extended-release niacin combination in the management of mixed dyslipidemias and primary hypercholesterolemia. Drug Healthc Patient Saf 2010 0.78
26 Attenuation of niacin-induced prostaglandin D(2) generation by omega-3 fatty acids in THP-1 macrophages and Langerhans dendritic cells. J Inflamm Res 2012 0.78
27 Managing mixed dyslipidemia in special populations. Prev Cardiol 2010 0.76
28 Niacin or ezetimibe for patients with, or at risk of coronary heart disease. Clin Med Insights Cardiol 2010 0.75
29 Statins for secondary prevention: might less in fact be more? Nat Rev Endocrinol 2011 0.75
Next 100